AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Dark Horse Resources

0.004

0.000

Volume:- -

Turnover:417.49K

Market Cap:19.17M

PE:-0.93

High:0.004

Open:0.004

Low:0.004

Close:0.004

52wk High:0.004

52wk Low:0.004

Shares:4.79B

Float Shares:2.92B

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.004

EPS(LYR):-0.004

ROE:-160.24%

ROA:-24.25%

PB:8.93

PE(LYR):-0.93

Loading ...

Overview Company News Filings

Is Danaher (DHR) Attractive After Recent Share Price Weakness?

Simply Wall St.

Update: Update: Masimo Shares Jump After Danaher Agrees to $180 per Share Cash Deal

MT Newswires Live

AI Concerns Linger, Driving Premarket Losses for US Equity Futures

MT Newswires Live

Top Premarket Decliners

MT Newswires Live

Top Premarket Gainers

MT Newswires Live

Assessing Danaher (DHR) Valuation After Earnings Beat And Optimistic Analyst Sentiment

Simply Wall St.

GUIDANCE: (DHR) Danaher Expects 2026 Adjusted EPS Range $8.35 to $8.50, vs. FactSet Est of $8.42

MT Newswires Live

How Slowing Organic Growth And Margin Pressure At Danaher (DHR) Has Changed Its Investment Story

Simply Wall St.

GUIDANCE: (DHR) Danaher Expects 2025 Adjusted EPS at High-End of Range $7.70 to $7.80, vs. FactSet Est of $7.71

MT Newswires Live

Assessing Danaher (DHR) Valuation As The Business Refocuses On Life Sciences And Diagnostics

Simply Wall St.

Danaher (DHR) Valuation Check After Analyst Upgrade and 2026 Earnings Recovery Narrative

Simply Wall St.

Danaher (DHR): Valuation Insights After Strong Q3 Earnings Beat and Upbeat Outlook

Simply Wall St.

Danaher (DHR): Profit Margins Decline to 14.4% Challenges Quality Premium Narrative

Simply Wall St.

GUIDANCE: (DHR) Danaher Expects 2025 Adjusted EPS Range $7.70 - $7.80

MT Newswires Live

Danaher (DHR): Examining Valuation as Shares Decline 12% Year-to-Date

Simply Wall St.

Will Danaher’s (DHR) AI Push and Tariff Tailwinds Reinforce Its Recurring Revenue Narrative?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DHR.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"DHR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DHR.AU\",,,,,undefined,":{"symbol":"DHR.AU","market":"AU","secType":"STK","nameCN":"Dark Horse Resources","latestPrice":0.004,"timestamp":1771995600000,"preClose":0.004,"halted":3,"volume":0,"delay":0,"changeRate":0,"nameEN":"Dark Horse Resources","floatShares":2916094918,"shares":4792470936,"eps":-0.004284,"marketStatus":"Halted","change":0,"latestTime":"02-25 16:00:00 AEDT","open":0.004,"high":0.004,"low":0.004,"amount":417485.568,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.004284,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1772060400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.004,"openAndCloseTimeList":[[1771974000000,1771995600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DHR.AU\",,,,,undefined,":{"symbol":"DHR.AU","floatShares":2916094918,"roa":"-24.25%","roe":"-160.24%","lyrEps":-0.004284,"shares":4792470936,"dividePrice":0,"high":0.004,"amplitude":0,"preClose":0.004,"low":0.004,"week52Low":0.004,"pbRate":"8.93","week52High":0.004,"institutionHeld":0,"latestPrice":0.004,"eps":-0.004284,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.004284,"open":0.004,"prevYearClose":0.004,"prevWeekClose":0.004,"prevMonthClose":0.004,"prevQuarterClose":0.004,"fiveDayClose":0.004,"twentyDayClose":0.004,"sixtyDayClose":0.004},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DHR.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DHR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DHR.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612413278","title":"Is Danaher (DHR) Attractive After Recent Share Price Weakness?","url":"https://stock-news.laohu8.com/highlight/detail?id=2612413278","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612413278?lang=en_us&edition=fundamental","pubTime":"2026-02-18 13:27","pubTimestamp":1771392421,"startTime":"0","endTime":"0","summary":"If you are wondering whether Danaher at around US$206 per share still offers good value, you are not alone. The answer depends on how you look at its underlying business and valuation.\nThe stock has recently been under pressure, with a 6.1% decline over the last week, a 12.6% decline over the last month and a 10.4% decline year to date, although the 1 year return sits at 1.5%.\nThese moves sit against a backdrop of ongoing interest in large, diversified life sciences and diagnostics...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/is-danaher-dhr-attractive-after-recent-share-price-weakness","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/is-danaher-dhr-attractive-after-recent-share-price-weakness","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","IE0004445239.USD","LU2125909247.SGD","SGXZ57979304.SGD","BK4121","DCF","LU0390134368.USD","LU0528227936.USD","SG9999013999.USD","BK4504","LU0708995401.HKD","LU2244417387.USD","LU0943347566.SGD","BK4533","IE00BQXX3C00.GBP","LU0097036916.USD","LU0289961442.SGD","LU0122379950.USD","LU1923621640.USD","LU1057294990.SGD","IE00BKVL7J92.USD","SG9999001176.SGD","LU1974910355.USD","LU0320765059.SGD","LU1791710582.SGD","LU0107464264.USD","LU0289739343.SGD","LU1917777945.USD","LU2063271972.USD","LU2265009873.SGD","LU2125910179.SGD","SG9999004303.SGD","LU2355687059.USD","LU2112291526.USD","LU0114720955.EUR","LU0109391861.USD","BK4581","LU0820561818.USD","LU2125909593.SGD","LU2211814178.USD","LU0882574055.USD","LU1267930730.SGD","LU0289960550.SGD","LU1923622614.USD","DHR","IE00BZ1G4Q59.USD","DHR.AU","LU1551013342.USD","LU1551013425.SGD","LU0511384066.AUD"],"gpt_icon":0},{"id":"2612465264","title":"Update: Update: Masimo Shares Jump After Danaher Agrees to $180 per Share Cash Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2612465264","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612465264?lang=en_us&edition=fundamental","pubTime":"2026-02-18 00:07","pubTimestamp":1771344454,"startTime":"0","endTime":"0","summary":"Masimo  shares jumped 34% Tuesday after Danaher  agreed to acquire the company for $180 per share in cash, or a total enterprise value of about $9.9 billion, including assumed indebtedness and net of acquired cash.Upon completion of the deal, expected in H2, Masimo will be a standalone operating company within Danaher's Diagnostics segment, Danaher said.\"We look forward to joining Danaher and continuing our growth and momentum as the global leader in patient monitoring,\" Masimo Chief Executive Katie Szyman said. \"Danaher shares our commitment to investing in talent and innovation and will be an ideal fit to help power the next chapter of Masimo.\"Price: 204.94, Change: -7.64, Percent Change: -3.59","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2211814178.USD","LU0240877869.USD","IE000M9KFDE8.USD","SG9999004303.SGD","LU2265009873.SGD","LU0820561909.HKD","DHR.AU","LU2764262908.HKD","LU0708995401.HKD","SG9999013999.USD","BK4121","LU2125910336.SGD","BK4504","LU2355687059.USD","LU0320765059.SGD","LU1023059063.AUD","BK4588","LU0289961442.SGD","LU1923621640.USD","LU0109391861.USD","LU0820561818.USD","LU0240878834.USD","DHR","LU1791710582.SGD","LU0312595415.SGD","LU0187121727.USD","LU2063271972.USD","LU2112291526.USD","LU0289960550.SGD","LU2244417387.USD","LU2720916845.USD","LU0882574055.USD","LU2125909593.SGD","LU0689472784.USD","LU2125910179.SGD","LU0205194284.USD","IE00BZ1G4Q59.USD","MASI","LU0511384066.AUD","LU0672654240.SGD","LU1804176565.USD","LU0205193047.USD","LU2764263039.SGD","LU0122379950.USD","BK4585","LU0157215616.USD","LU0390134368.USD","BK4533","IE00BKVL7J92.USD","BK4534"],"gpt_icon":0},{"id":"2612745043","title":"AI Concerns Linger, Driving Premarket Losses for US Equity Futures","url":"https://stock-news.laohu8.com/highlight/detail?id=2612745043","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612745043?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:06","pubTimestamp":1771337207,"startTime":"0","endTime":"0","summary":"US equity futures were down ahead of Tuesday's opening bell, with futures of technology-heavy Nasdaq Composite leading declines amid lingering concerns about artificial intelligence-driven disruption.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IVOO","VTI","ZIM.AU","MASI","UDOW","JEPQ","QYLG","SDOW",".IXIC","GPIX","SPY","DDM","QYLD","TQQQ","QQQJ","TSYW.SI","SSO","ZIM","DHR.AU","QQQE","USJW.SI","QQQY","SPXU","EQR",".DJI","PSQ","VOOV","HIBL","NVIW.SI","VMC","IVW","SPYV","BMAY","GPIQ","QID","XDTE","SH","USAW.SI",".SPX","QLD","VMC.AU","SCHD","SPXL","DXD","MNQmain","MDT","QQQM","DHR","SDS"],"gpt_icon":1},{"id":"2612454426","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2612454426","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612454426?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:40","pubTimestamp":1771332054,"startTime":"0","endTime":"0","summary":"Vulcan Materials  stock was down 7% pre-bell Tuesday after the company reported lower Q4 adjusted earnings year over year.Genuine Parts  shares were 7% lower after the company reported lower Q4 adjusted earnings and announced a plan to separate its automotive and industrial parts groups into two independent, publicly traded entities.Danaher  stock was down 6.9% after the Financial Times reported that the company is close to acquiring Masimo  in a deal worth about $10 billion.Medtronic  shares were 3.7% lower after the company reported lower fiscal Q3 non-GAAP earnings.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VMC.AU","LU2125910179.SGD","LU0950375773.USD","LU0240878834.USD","LU2355687059.USD","LU0312595415.SGD","SG9999004303.SGD","GPC","LU1571399168.USD","LU1989771016.USD","LU1057294990.SGD","LU2506951958.HKD","SG9999001176.SGD","LU0114720955.EUR","LU0320765059.SGD","SGXZ57979304.SGD","IE00BQXX3F31.USD","LU0820561909.HKD","DHR.AU","VMC","LU1974910355.USD","LU1989764748.USD","LU2063271972.USD","IE0004445239.USD","LU2106854487.HKD","LU0265550359.USD","LU2023250504.SGD","MASI","LU0390134368.USD","LU0820561818.USD","MDT","LU0943347566.SGD","LU0823417737.USD","LU2764263039.SGD","IE00B42XCP33.USD","LU0175139822.USD","LU0511384066.AUD","LU1983299246.USD","LU2237443382.USD","IE00BFXG1179.USD","LU2125910336.SGD","LU0528227936.USD","LU2244417387.USD","BK4082","LU2271345857.HKD","LU2720916845.USD","LU0211326755.USD","LU0265550946.USD","BK4566","DHR"],"gpt_icon":0},{"id":"2612543234","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2612543234","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612543234?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:25","pubTimestamp":1771331140,"startTime":"0","endTime":"0","summary":"Tg-17  shares were 93% higher pre-bell Tuesday, rebounding from Friday's losses.ZIM Integrated Shipping Services  stock was up 35%, a day after the company said it has agreed to be acquired by Hapag-Lloyd in a deal worth about $4.2 billion.Masimo  shares were 34% higher after the Financial Times reported that Danaher  is close to acquiring the medical technology company in a deal worth $10 billion.Compass Pathways  stock was up past 23% after the company said that a second phase 3 trial of COMP360 for treatment-resistant depression achieved its primary endpoint.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DHR.AU","LU0390134368.USD","LU1804176565.USD","LU0122379950.USD","IE000M9KFDE8.USD","BK4585","LU0312595415.SGD","LU1551013425.SGD","IE00BQXX3D17.EUR","LU1923621640.USD","LU2764263203.CNY","SG9999004303.SGD","OBAI","LU0320765059.SGD","LU2244417387.USD","MASI","LU0175139822.USD","LU2063271972.USD","IE00BZ1G4Q59.USD","LU0882574055.USD","LU2355687059.USD","LU1791710582.SGD","LU1023059063.AUD","LU0114720955.EUR","BK4534","LU1061106388.HKD","LU2023250504.SGD","ZIM","LU1974910355.USD","BK4533","LU2106854487.HKD","ZIM.AU","LU1057294990.SGD","LU0528227936.USD","CMPS","LU0289960550.SGD","DHR","LU1267930730.SGD","LU0205194284.USD","IE0004445239.USD","IE00BQXX3F31.USD","SG9999013999.USD","LU1551013342.USD","LU2265009873.SGD","LU0157215616.USD","IE00BQXX3C00.GBP","LU2125909247.SGD","LU0240877869.USD","LU2720916845.USD","SGXZ57979304.SGD"],"gpt_icon":0},{"id":"2610964887","title":"Assessing Danaher (DHR) Valuation After Earnings Beat And Optimistic Analyst Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2610964887","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610964887?lang=en_us&edition=fundamental","pubTime":"2026-02-12 05:15","pubTimestamp":1770844509,"startTime":"0","endTime":"0","summary":"Danaher (DHR) shares have reacted to a busy stretch of news, with quarterly results that topped Wall Street revenue forecasts. Adjusted EPS growth has drawn attention despite the stock lagging the broader market over the past year.\nSee our latest analysis for Danaher.\nAt around $219.75, Danaher's recent 1-day and 7-day share price returns of about 1% suggest a modest positive reaction to the earnings beat and board changes. The 1-year total shareholder return of roughly 10% contrasts with...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/assessing-danaher-dhr-valuation-after-earnings-beat-and-opti","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/assessing-danaher-dhr-valuation-after-earnings-beat-and-opti","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DHR.AU","DHR"],"gpt_icon":0},{"id":"2606790183","title":"GUIDANCE: (DHR) Danaher Expects 2026 Adjusted EPS Range $8.35 to $8.50, vs. FactSet Est of $8.42","url":"https://stock-news.laohu8.com/highlight/detail?id=2606790183","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606790183?lang=en_us&edition=fundamental","pubTime":"2026-01-28 19:02","pubTimestamp":1769598158,"startTime":"0","endTime":"0","summary":"GUIDANCE: (DHR) Danaher Expects 2026 Adjusted EPS Range $8.35 to $8.50, vs. FactSet Est of $8.42","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DHR.AU","DHR"],"gpt_icon":0},{"id":"2605496484","title":"How Slowing Organic Growth And Margin Pressure At Danaher (DHR) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2605496484","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605496484?lang=en_us&edition=fundamental","pubTime":"2026-01-21 22:33","pubTimestamp":1769005986,"startTime":"0","endTime":"0","summary":"In recent months, Danaher has reported mixed quarterly results and guidance, while also outlining expectations for mid‑single‑digit sales growth and adjusted diluted EPS in 2025 during past investor updates.\nAt the same time, the company’s core business has faced pressure, with organic revenue, operating margins and free cash flow margins all moving lower over multi‑year periods, prompting debate about the quality of its underlying performance.\nWe’ll now examine how these pressures on...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/how-slowing-organic-growth-and-margin-pressure-at-danaher-dh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/how-slowing-organic-growth-and-margin-pressure-at-danaher-dh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2063271972.USD","LU2244417387.USD","LU2106854487.HKD","BK4581","LU1267930730.SGD","LU2211814178.USD","SGXZ23171101.USD","LU0708995401.HKD","LU2355687059.USD","BK4121","LU2112291526.USD","LU1057294990.SGD","LU1791710400.SGD","IE00BQXX3C00.GBP","LU0820561909.HKD","LU0109391861.USD","LU0187121727.USD","LU0820562030.AUD","IE00BZ1G4Q59.USD","LU0289961442.SGD","LU0312595415.SGD","BK4504","LU1366333091.USD","LU1023059063.AUD","LU1791710582.SGD","SG9999001176.USD","LU0528227936.USD","LU1917777945.USD","LU0432979614.USD","LU2125910336.SGD","LU0114720955.EUR","IE00BKVL7J92.USD","LU1551013342.USD","BK4588","LU2125909247.SGD","LU1804176565.USD","DHR","LU1923622614.USD","DHR.AU","LU0820561818.USD","LU2125909593.SGD","LU0157215616.USD","IE00BQXX3F31.USD","LU0672654240.SGD","LU1923621640.USD","LU0175139822.USD","LU2023250504.SGD","LU0320765059.SGD","IE000M9KFDE8.USD","LU1551013425.SGD"],"gpt_icon":0},{"id":"2602454549","title":"GUIDANCE: (DHR) Danaher Expects 2025 Adjusted EPS at High-End of Range $7.70 to $7.80, vs. FactSet Est of $7.71","url":"https://stock-news.laohu8.com/highlight/detail?id=2602454549","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602454549?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:19","pubTimestamp":1768227587,"startTime":"0","endTime":"0","summary":"GUIDANCE: (DHR) Danaher Expects 2025 Adjusted EPS at High-End of Range $7.70 to $7.80, vs. FactSet Est of $7.71","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DHR.AU","DHR"],"gpt_icon":0},{"id":"2601819037","title":"Assessing Danaher (DHR) Valuation As The Business Refocuses On Life Sciences And Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2601819037","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601819037?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:23","pubTimestamp":1767709439,"startTime":"0","endTime":"0","summary":"Recent attention on Danaher (DHR) centers on its decision to spin off non core operations and place more emphasis on life sciences, biotechnology tools, and diagnostics, a shift that is reshaping how investors view the business.\nSee our latest analysis for Danaher.\nDanaher’s focus on life sciences and diagnostics sits against a backdrop of a 14.83% 90 day share price return to US$235.36, while its 1 year total shareholder return of a 0.95% decline suggests recent momentum has been stronger...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/assessing-danaher-dhr-valuation-as-the-business-refocuses-on","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/assessing-danaher-dhr-valuation-as-the-business-refocuses-on","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2063271972.USD","LU2244417387.USD","LU0390134368.USD","BK4585","LU1267930730.SGD","LU1974910355.USD","LU2211814178.USD","SGXZ23171101.USD","LU2125910179.SGD","LU0708995401.HKD","BK4533","LU2355687059.USD","BK4121","LU2112291526.USD","LU0511384066.AUD","LU1057294990.SGD","LU1791710400.SGD","IE00BQXX3C00.GBP","LU0107464264.USD","LU0109391861.USD","SGXZ57979304.SGD","LU0289961442.SGD","SG9999001176.SGD","IE0004445239.USD","LU1366333091.USD","LU1023059063.AUD","LU0882574055.USD","SG9999001176.USD","BK4534","LU0528227936.USD","LU1917777945.USD","LU2265009873.SGD","SG9999013999.USD","LU2125910336.SGD","IE00BKVL7J92.USD","LU0943347566.SGD","BK4588","LU2125909247.SGD","LU1804176565.USD","DHR","DHR.AU","LU0820561818.USD","LU0157215616.USD","IE00BQXX3F31.USD","LU0672654240.SGD","LU1923621640.USD","LU2023250504.SGD","LU0320765059.SGD","IE000M9KFDE8.USD","LU1551013425.SGD"],"gpt_icon":0},{"id":"2589839754","title":"Danaher (DHR) Valuation Check After Analyst Upgrade and 2026 Earnings Recovery Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2589839754","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589839754?lang=en_us&edition=fundamental","pubTime":"2025-12-05 00:20","pubTimestamp":1764865242,"startTime":"0","endTime":"0","summary":"Morgan Stanley’s upgrade of Danaher (DHR) has put the stock back on many watchlists, as the firm leans into a 2026 recovery story built on core revenue growth and earnings leverage.\nSee our latest analysis for Danaher.\nThat optimism has helped the stock regain some momentum, with a 30 day share price return of 6.73 percent and a 90 day share price return of 14.79 percent, even though the 1 year total shareholder return is still slightly negative.\nIf Danaher’s recovery story has your...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-valuation-check-after-analyst-upgrade-and-2026-e","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-valuation-check-after-analyst-upgrade-and-2026-e","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DHR","DHR.AU"],"gpt_icon":0},{"id":"2578637189","title":"Danaher (DHR): Valuation Insights After Strong Q3 Earnings Beat and Upbeat Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2578637189","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578637189?lang=en_us&edition=fundamental","pubTime":"2025-10-26 16:19","pubTimestamp":1761466791,"startTime":"0","endTime":"0","summary":"Danaher (NYSE:DHR) delivered strong third quarter results, with both sales and net income rising year-on-year. The company beat Wall Street’s revenue expectations, powered in part by steady demand for monoclonal antibody production and earlier than usual respiratory testing orders.\nSee our latest analysis for Danaher.\nDanaher’s upbeat third quarter sealed a turn in sentiment, with the stock jumping nearly 6% in a single day and gaining over 20% in the past month alone. While the 1-year total...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-valuation-insights-after-strong-q3-earnings-beat","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-valuation-insights-after-strong-q3-earnings-beat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DHR.AU","DHR"],"gpt_icon":0},{"id":"2577258022","title":"Danaher (DHR): Profit Margins Decline to 14.4% Challenges Quality Premium Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2577258022","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577258022?lang=en_us&edition=fundamental","pubTime":"2025-10-23 20:34","pubTimestamp":1761222853,"startTime":"0","endTime":"0","summary":"Danaher (DHR) saw its earnings decline by 5.6% per year over the past five years, and most recently reported negative earnings growth again. Net profit margins narrowed to 14.4%, down from 16.6% last year, while shares currently trade at $218.10, below the estimated fair value of $233.28. Revenue is expected to grow at 5.2% per year, which trails the US market average of 10%. However, earnings are forecast to accelerate at 16.7% annually, outpacing the 15.5% average for the broader market...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-profit-margins-decline-to-144-challenges-quality","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-profit-margins-decline-to-144-challenges-quality","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1791710582.SGD","LU2265009873.SGD","SG9999004303.SGD","LU0175139822.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0390134368.USD","LU1551013425.SGD","LU1267930730.SGD","SG9999001176.SGD","LU0708995401.HKD","LU2023250504.SGD","LU0528227936.USD","IE0004445239.USD","SGXZ23171101.USD","LU0820561818.USD","BK4585","BK4588","BK4504","LU0122379950.USD","LU0689472784.USD","LU2355687059.USD","LU1366333091.USD","DHR","BK4533","LU2063271972.USD","LU2125909247.SGD","LU0820561909.HKD","LU0109391861.USD","LU2106854487.HKD","LU0289961442.SGD","BK4534","LU1804176565.USD","SGXZ57979304.SGD","SG9999001176.USD","LU1917777945.USD","LU1551013342.USD","LU0312595415.SGD","DHR.AU","LU0432979614.USD","LU1791710400.SGD","LU2125910179.SGD","LU1974910355.USD","LU1923621640.USD","BK4121","LU0820562030.AUD","LU0187121727.USD","LU0114720955.EUR","IE000M9KFDE8.USD","LU0289960550.SGD"],"gpt_icon":0},{"id":"2577251808","title":"GUIDANCE: (DHR) Danaher Expects 2025 Adjusted EPS Range $7.70 - $7.80","url":"https://stock-news.laohu8.com/highlight/detail?id=2577251808","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577251808?lang=en_us&edition=fundamental","pubTime":"2025-10-21 18:03","pubTimestamp":1761040986,"startTime":"0","endTime":"0","summary":"GUIDANCE: (DHR) Danaher Expects 2025 Adjusted EPS Range $7.70 - $7.80","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DHR.AU","DHR"],"gpt_icon":0},{"id":"2574454997","title":"Danaher (DHR): Examining Valuation as Shares Decline 12% Year-to-Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2574454997","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574454997?lang=en_us&edition=fundamental","pubTime":"2025-10-11 22:25","pubTimestamp":1760192706,"startTime":"0","endTime":"0","summary":"Danaher (DHR) shares have edged downward recently as broader market conditions influence sentiment. This has prompted investors to weigh the company’s financials and longer-term trends. With a mixed performance over the past year, Danaher remains on watch.\nSee our latest analysis for Danaher.\nDanaher's share price has slipped nearly 12% year-to-date and logged a 1-year total shareholder return of -24.7%. While short-term moves have been choppy, recent selling suggests investors may be...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-examining-valuation-as-shares-decline-12-year-to","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/danaher-dhr-examining-valuation-as-shares-decline-12-year-to","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE0004445239.USD","LU0882574055.USD","BK4121","LU1061106388.HKD","SG9999004303.SGD","LU1791710400.SGD","LU2063271972.USD","LU2023250504.SGD","LU2244417387.USD","LU1974910355.USD","LU0672654240.SGD","LU0708995401.HKD","LU0943347566.SGD","LU1023059063.AUD","LU1923622614.USD","IE00BZ1G4Q59.USD","LU0187121727.USD","LU0820561909.HKD","LU2125910336.SGD","DHR","LU2125909247.SGD","BK4581","SG9999001176.USD","LU0175139822.USD","LU2125910179.SGD","LU1551013425.SGD","SG9999013999.USD","LU0122379950.USD","LU0097036916.USD","LU0820561818.USD","LU0312595415.SGD","LU2106854487.HKD","SG9999001176.SGD","LU0107464264.USD","IE000M9KFDE8.USD","SGXZ23171101.USD","BK4534","IE00BKVL7J92.USD","LU0289739343.SGD","LU0511384066.AUD","SGXZ57979304.SGD","LU1923621640.USD","LU0528227936.USD","LU1551013342.USD","LU2265009873.SGD","LU0432979614.USD","LU0320765059.SGD","LU2112291526.USD","LU1804176565.USD","DHR.AU"],"gpt_icon":0},{"id":"2573285416","title":"Will Danaher’s (DHR) AI Push and Tariff Tailwinds Reinforce Its Recurring Revenue Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2573285416","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573285416?lang=en_us&edition=fundamental","pubTime":"2025-10-06 05:18","pubTimestamp":1759699132,"startTime":"0","endTime":"0","summary":"In recent days, Danaher's Leica Biosystems unit announced the launch of new AI-powered digital pathology solutions, alongside favorable changes in US pharmaceutical tariffs supporting domestic companies in the sector.\nThis combination of technological innovation and shifts in the regulatory landscape is enhancing confidence in Danaher's position within Life Sciences and Diagnostics.\nWe'll examine how Danaher's new AI-powered pathology platform may support its narrative of recurring revenue...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/will-danahers-dhr-ai-push-and-tariff-tailwinds-reinforce-its","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/will-danahers-dhr-ai-push-and-tariff-tailwinds-reinforce-its","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DHR.AU","DHR"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}